S100A12: Friend or foe in pulmonary tuberculosis?
S100A12: Friend or foe in pulmonary tuberculosis?
复制标题
DOI：
10.1016/j.cyto.2017.01.009
复制
发表时间：
2017-04-01
期刊：
影响因子：
3.8
通讯作者：
Bagheri, Vahid
中科院分区：
文献类型：
--
作者：
Bagheri, Vahid
在人类中，S100A12(又称钙粒蛋白C和ENRAGE)主要由中性粒细胞表达和分泌。细胞外S100A12参与针对微生物和寄生虫的先天免疫反应。S100A12是晚期糖基化终产物受体(RAGE)的配体，RAGE是巨噬细胞、内皮细胞和淋巴细胞上的细胞表面受体。在最近的一项研究中，Realegeno等人。结果表明，S100A12对感染人巨噬细胞的麻风分枝杆菌具有一定的抗菌活性。最近，关于S100A12的抗菌活性的一些有趣的数据被报道。另一种新发现的受体Toll样受体4(TLR4)支持S100A12的促炎作用。这些观察结果强调了S100A12对于开发潜在的治疗方法以提高保护性免疫或减少免疫发病机制的重要性。(C)2017爱思唯尔有限公司。保留所有权利。
In humans, S100A12 (also named Calgranulin C and EN-RAGE) is mainly expressed and secreted by neutrophil granulocytes. Extracellular S100A12 is involved in innate immune responses against microorganisms and parasites. S100A12 is a ligand for the receptor for advanced glycation end products (RAGE), which is a cell surface receptor on macrophages, endothelium, and lymphocytes. In a recent study, Realegeno et al. showed that S100A12 exerts antimicrobial activity against Mycobacterium leprae in infected human macrophages. Recently, some interesting data on the antimicrobial activity of S100A12 have been reported. Proinflammatory role of S100A12 is supported by another newly found receptor, Toll-like receptor 4 (TLR4). These observations emphasize the importance of S100A12 for the development of potential therapeutic approaches to increase protective immunity or reduce immunopathogenesis. (C) 2017 Elsevier Ltd. All rights reserved.